This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D81.7 | Synonyms: MHC class II deficiency, Bare lymphocyte syndrome type II (BLS II), HLA class II deficiency
MHC class II deficiency first became known when Griscelli et al. in 1979 reported immunodeficient children whose cell surfaces did not express HLA-DR, -DQ, and -DP molecules. It was initially named 'Bare lymphocyte syndrome', and as the distinction from HLA class I deficiency (BLS type I) later became clear, it was reclassified as BLS type II.
In the 1990s, advances in cloning technology led to the successive identification of the transcriptional regulators required for MHC class II gene expression. It was confirmed that transcription factors such as CIITA (MHC Class II Transactivator), identified by Reith et al. in 1993, and RFXANK, RFX5, and RFXAP, identified by Steimle et al. in 1994, are essential for MHC II expression.
By molecular cause, MHC II deficiency is classified into four complementation groups: A (CIITA variants), B (RFXANK variants), C (RFX5 variants), and D (RFXAP variants). The most common cause is RFXANK (or RFX-B) variants, which cluster in North Africa because of a founder effect.
In Korea, MHC II deficiency is a very rare disease, and a small number of cases are diagnosed and managed at institutions specializing in primary immunodeficiency.
Expression of the MHC class II genes (HLA-DR, HLA-DQ, HLA-DP) is regulated by the RFX transcription complex (RFX5, RFXANK, RFXAP) and CIITA. The RFX complex binds to the X box of MHC II gene promoters, and CIITA, as a coactivator, is essential for transcriptional activation by the RFX complex.
| Complementation group | Gene | Location | Features |
|---|---|---|---|
| A | CIITA | 16p13.13 | MHC II transcriptional coactivator; clinical course relatively mild in some cases |
| B | RFXANK | 19p12 | Most common; North African founder effect |
| C | RFX5 | 1q21.3 | Component of the RFX complex |
| D | RFXAP | 13q14.11 | Component of the RFX complex |
RFXANK variants (especially the Gln67X premature termination variant) cluster in North Africa and the Middle East because of a founder effect, and homozygous RFXANK variants are identified in a substantial proportion of patients from these regions.
Inheritance is autosomal recessive. All four causative genes (CIITA, RFXANK, RFX5, RFXAP) are located on autosomes. The parents are carriers, and 25% of their children are affected.
All four complementation groups show the same phenotype (loss of HLA II expression, reduced CD4+ T cells). Clinical severity does not differ greatly by complementation group, but a relatively mild clinical course has been reported in some cases with CIITA variants (complementation group A).
Various point mutations, deletions, and splicing variants have been reported in each gene. In particular, the RFXANK Gln67X variant is repeatedly identified in North African patients.
Carriers can be identified among parents and siblings by molecular genetic testing. Carriers show normal HLA II expression and have no clinical symptoms.
MHC II deficiency is a rare primary immunodeficiency, with about 200 cases reported worldwide. The populations most frequently reported are those of North African (Morocco, Algeria, Tunisia) and Middle Eastern (Saudi Arabia, Iran) origin.
Symptoms mainly appear between a few months of age and 2 years. There is no sex difference. Later onset has been reported in some cases.
In Korea, MHC II deficiency is very rare, and a small number of patients managed at primary immunodeficiency centers (such as university hospitals in Seoul and Busan) have been reported. Given the ethnic background in Korea, the North African founder variant is presumed to be rare, with diverse variants occurring sporadically.
MHC II molecules on the surface of thymic cortical epithelial cells are essential for positive selection of CD4+ T cells in the thymus. When MHC II expression is lost, positive selection of CD4+ T cells does not occur, and CD4+ T cells are markedly reduced or absent in peripheral blood.
CD4+ T cells (helper T cells) help B cells produce antibodies, promote CD8+ T-cell activation, and are involved in macrophage activation. When CD4+ T cells are deficient, all of these effector immune functions decline, resulting in a state of combined immunodeficiency.
B-cell numbers are normal, but without T-cell help, class switching and production of high-affinity antibodies are impossible. As a result, serum immunoglobulins (IgG, IgA, IgM) are all reduced, or a pattern of normal IgM with reduced IgG and IgA appears.
CD8+ T cells and NK cells can function independently without CD4+ T-cell help, but integrated cell-mediated immunity is reduced, making patients highly vulnerable to intracellular pathogens (mycobacteria, opportunistic viruses, fungi).
Most patients first develop symptoms between 6 months and 2 years of age with recurrent severe infections. This coincides with the time when maternally transferred antibodies disappear.
Bacterial infections (pneumonia, otitis media, meningitis; pneumococcus, Haemophilus, meningococcus), viral infections (pneumonia due to CMV, EBV, adenovirus, parainfluenza virus), fungal infections (Pneumocystis jirovecii pneumonia, Candida, Aspergillus), and opportunistic infections (chronic diarrhea due to Cryptosporidium) are frequent.
Chronic diarrhea, malabsorption, and failure to thrive due to Cryptosporidium and other opportunistic pathogens are common. Sclerosing cholangitis can develop as a complication of Cryptosporidium infection.
Disseminated BCG infection develops after BCG vaccination, and in Korea as well, disseminated BCG infection after BCG vaccination sometimes appears as the first manifestation of the immunodeficiency.
Physical examination shows failure to thrive, weight loss, oral candidiasis, and stomatitis. Absent or atrophic lymph nodes without lymphadenopathy are characteristic. Abnormal auscultation findings (crackles, wheezes) due to recurrent pneumonia and chronic cough are seen.
Lymphocyte subset analysis is characterized by marked reduction or absence of CD4+ T cells. CD8+ T cells are normal or increased. B-cell numbers are normal, but serum IgG and IgA are reduced. Flow cytometry shows loss or marked reduction of HLA-DR (MHC II) expression. In lymphocyte proliferation testing, the proliferative response to alloantigens (MLR, mixed lymphocyte reaction) is reduced.
Chest CT shows interstitial lung disease, pneumonia, bronchiectasis, and atelectasis. Sclerosing cholangitis may be confirmed on abdominal CT or MRCP.
MHC II deficiency may be detected by TREC-based newborn screening, but because the pattern of CD4+ T-cell reduction is not specific, complementary confirmatory testing is needed.
Primary immunodeficiency is suspected in infants older than 6 months with recurrent opportunistic infections, chronic diarrhea, and failure to thrive. Parental consanguinity and a similar history in family members are checked.
After a complete blood count, lymphocyte subset analysis (confirming a marked reduction in CD4+ T cells), flow cytometry for HLA-DR expression, and quantification of serum immunoglobulins (whether IgG, IgA, IgM are reduced) are performed.
In Korea, the diagnosis is made by immunological testing in infants referred for disseminated infection after BCG vaccination or symptoms of recurrent opportunistic infection. Introduction of a TREC-based screening program is expected to make early detection possible.
The key diagnostic finding is loss or marked reduction of HLA-DR, -DQ, and -DP expression on the surface of peripheral blood lymphocytes on flow cytometry using HLA-DR (or pan-MHC II) antibodies. It is confirmed together with a reduction in CD4+ T cells.
The complementation group can be determined by a complementation assay, in which patient cells are fused with cell lines of each complementation group to see whether MHC II expression is restored, but in practice the causative gene is identified directly by molecular genetic testing.
Pathogenic variants are identified by Sanger sequencing or NGS panel testing of the CIITA, RFXANK, RFX5, and RFXAP genes. In patients of North African or Middle Eastern ancestry, the RFXANK Gln67X variant can be checked first.
Reduced proliferative response in the mixed lymphocyte reaction (MLR). Reduced antigen-specific lymphocyte proliferative responses. Functional antibody production capacity is assessed by serum immunoglobulin quantification and antibody titer testing.
The only curative treatment for MHC II deficiency is allogeneic hematopoietic stem cell transplantation. Transplantation from an HLA-matched sibling or unrelated donor is the standard treatment. Performing transplantation as early as possible after diagnosis, before infectious complications develop, is critically important for success rates and prognosis.
Antibody deficiency is compensated with intravenous immunoglobulin (IVIG). TMP-SMX for prevention of Pneumocystis pneumonia, fluconazole for Candida prophylaxis, and ganciclovir/valganciclovir for CMV prophylaxis are administered.
When disseminated infection develops after BCG vaccination, antituberculosis treatment (isoniazid + rifampin ± ethambutol) is maintained long term while transplantation proceeds.
Live vaccines such as BCG, MMR, varicella, and rotavirus are absolutely contraindicated. For transfusions, irradiated, CMV-negative, leukocyte-depleted blood products are used.
Without treatment, most patients with MHC II deficiency die of infection within the first few years of life. In particular, sclerosing cholangitis due to Cryptosporidium progresses even after transplantation and worsens the prognosis.
Long-term survival is possible with early transplantation. Transplant success and long-term survival rates are high with HLA-matched sibling donor transplantation. However, when complications (sclerosing cholangitis, chronic lung disease) have already progressed before transplantation, morbidity remains high after transplantation.
In patients who developed sclerosing cholangitis due to Cryptosporidium, liver disease may persist after transplantation. Chronic lung disease, nutritional impairment, and failure to thrive are the main causes of morbidity in long-term survivors.
Carrier testing of both parents and genetic counseling on the risk in subsequent pregnancies are essential.
In pregnant women with a family history, whether the fetus is affected is determined after confirming the fetal genotype by CVS or amniocentesis. In in vitro fertilization, PGT-M can prevent implantation of affected embryos.
When MHC II deficiency is strongly suspected or confirmed, BCG vaccination is never given. In newborns suspected because of a family history, immune evaluation is performed before BCG vaccination.
Expanded introduction of TREC-based newborn screening programs is key to early diagnosis and improved treatment outcomes.